Skip to content

Analgesic Efficacy of Quadro-Iliac Plane Block Versus Erector Spinae Plane in Total Hip Arthroplasty

Analgesic Efficacy of Quadro-Iliac Plane Block Versus Erector Spinae Plane in Total Hip Arthroplasty: A Randomized Non-Inferiority Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07537036
Enrollment
76
Registered
2026-04-17
Start date
2026-04-18
Completion date
2026-10-01
Last updated
2026-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Analgesic Efficacy, Quadro-Iliac Plane Block, Erector Spinae Plane Block, Total Hip Arthroplasty

Brief summary

This study aims to compare the Quadro-Iliac Plane Block versus Erector Spinae Plane Block after total hip arthroplasty.

Detailed description

Total hip arthroplasty (THA) is frequently utilized in elderly patients to address hip pain and restore joint function. Effective postoperative pain management is critical; however, the use of opioids is associated with a range of adverse effects, including nausea, vomiting, pruritus, constipation, respiratory depression, and the risk of dependence. Quadro-iliac plane block (QIPB) has been introduced, combining elements of both posterior and anterior QLB approaches. Erector Spinae Plane Block (ESPB) was initially described as an analgesic approach for managing thoracic neuropathic pain. This innovative fascial block technique enables sensory blockade across multiple abdominal and thoracic wall segments.

Interventions

Patients will receive ipsilateral Quadro-iliac plane block (QIPB) using 20ml of bupivacaine 0.25%.

OTHERErector spinae plane block

Patients will receive ipsilateral erector spinae plane block (ESPB) using 20ml of bupivacaine 0.25%.

Sponsors

Tanta University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 years. * Both sexes. * American Society of Anesthesiology (ASA) physical status I-III. * Undergoing total hip arthroplasty (THA) under spinal anesthesia.

Exclusion criteria

* History of allergies to local anesthetics. * Opioid dependency. * Body mass index (BMI) \> 35 kg/m2. * Cognitive impairment. * Bleeding or coagulation disorders. * Psychiatric and neurological disorder. * Local infection at the site of injection. * Severe heart, lung, liver, and renal dysfunction. * Emergency surgery.

Design outcomes

Primary

MeasureTime frameDescription
Time to the first rescue analgesia24 hours postoperativelyTime to the first request for the rescue analgesia will be recorded from the end of surgery to first dose of morphine administrated.

Secondary

MeasureTime frameDescription
Total morphine consumption24 hours postoperativelyRescue analgesia of morphine will be given as 3 mg bolus if the numeric rating scale (NRS) \> 3 to be repeated after 30 min if pain persists until the NRS \< 4.
Degree of pain24 hours postoperativelyEach patient will be instructed about postoperative pain assessment with the numeric rating scale (NRS). NRS (0 represents "no pain" while 10 represents "the worst pain imaginable"). NRS will be assessed at post-anesthesia care unit (PACU), 2, 4, 6, 8, 12, 18, and 24 h postoperatively.
Quality of recovery24 hours postoperativelyThe quality of recovery (QoR-15) score, will be assessed 24 hours postoperatively. This tool consists of 15 questions, each scored on a 10-point scale, yielding a maximum of 150. It encompasses five domains; physical comfort (questions 1-4, 13), emotional state (questions 9, 10, 14, 15), psychological support (questions 6, 7), physical independence (questions 5, 8), and pain (questions 11, 12
Incidence of adverse events24 hours postoperativelyIncidence of adverse events such as bradycardia, hypotension, nausea, vomiting, respiratory depression, pruritus, or any other complication will be recorded.

Countries

Egypt

Contacts

CONTACTMohammed S Elsharkawy, MD
mselsharkawy@med.tanta.edu.eg00201148207870

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 22, 2026